Manufacturer Engagement In ICER Reviews Widespread; How Much It Helps Is Less Clear
Tufts study evaluates the extent and impact of manufacturer engagement with the Institute for Clinical and Economic Review while recent survey by Xcenda finds payer reliance on ICER reports is growing.
You may also be interested in...
AHIP arrangement is a big win for ICER and will facilitate access to the organization’s cloud-based cost effectiveness review platform for a broad range of payers, particularly small and mid-size companies that may not have the resources to subscribe to the service on their own.
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.